Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Part A study of intravitreal fludrocortisone acetate for geographic atrophy secondary to AMD
ACTRN12624000971538Phase 2Completed
- Sponsor
- Eye Co
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludrocortisone in age-related macular degeneration (AMD), sponsored by Eye Co. Primary endpoints: Safety and tolerability of multiple doses of intravitreal fludrocortisone acetate, Urine pregnancy test and 4 more. Started Jan 2025; status: completed.
02
Drugs
fludrocortisone
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ACTRN12624000971538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000971538.